Phio Pharmaceuticals Corp.
PHIONext catalyst
No upcoming catalyst in our data
No upcoming FDA decision, filing or trial readout is on file for PHIO. That does not mean none is planned.
Get an email about PHIO's next catalysts
Track Phio Pharmaceuticals (PHIO) and we email you when an FDA date moves, 7 days and 1 day before the decision when the exact day is known, and when it is announced. Free account, no card.
1 upcoming event in our data (regulatory event).See the timeline
1 upcoming, 2 past
Regulatory Decision - PH-762
For cutaneous squamous cell carcinoma, melanoma, Merkel cell carcinoma. Phio Pharmaceuticals reported Q3 2026 results and a business update, noting completion of the Phase 1b trial of PH-762 (22 patients), release of its first commercial-scale cGMP drug substance batch, and submission of regulatory documents to FDA. An FDA response is expected by end of November 2026, with Phase 2b initiation planned for Q1 2027.
SourceMarket Overview
Stock performance and key metrics
No drugs found in this phase.
Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)
Frequently asked questions
When is Phio Pharmaceuticals Corp.'s next FDA catalyst?β
CatalystAlert tracks every upcoming catalyst for Phio Pharmaceuticals Corp. (PHIO) β PDUFA decision dates, Phase 1/2/3 trial readouts, FDA advisory committee meetings and NDA/BLA filings β each confidence-rated as confirmed, estimated or AI-detected.
How do I track PHIO biotech catalysts?β
Add PHIO to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Phio Pharmaceuticals Corp.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page β sourced from ClinicalTrials.gov, FDA and SEC filings.
